Recursion Pharmaceuticals (RXRX) Non-Current Deffered Revenue (2020 - 2026)

Recursion Pharmaceuticals has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $114.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 11.49% year-over-year to $114.7 million; the trailing twelve-month figure through Mar 2026 stood at $114.7 million (down 11.49% YoY), and the FY2025 full-year result was $114.0 million, down 4.0% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $114.7 million, up from $114.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $129.6 million in Q1 2025, with the low at $15.7 million in Q3 2024.
• Historically, Non-Current Deffered Revenue has averaged $76.9 million across 5 years, with a median of $70.3 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue soared 2704.93% — and 2024, when it sank 69.42%.
• Recursion Pharmaceuticals' Non-Current Deffered Revenue stood at $70.3 million in 2022, then fell by 27.07% to $51.2 million in 2023, then soared by 131.79% to $118.8 million in 2024, then retreated by 4.0% to $114.0 million in 2025, then advanced by 0.62% to $114.7 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $114.7 million (Q1 2026), $114.0 million (Q4 2025), and $111.2 million (Q3 2025), per Business Quant data.